Complications of intravesical bcg immunotherapy for bladder cancer

Daniel B. Green, Akira Kawashima, Christine O. Menias, Takashi Tanaka, Gil Redelman-Sidi, Sanjeev Bhalla, Rakesh Shah, Bernard Francis King

Research output: Contribution to journalArticle

Abstract

Bladder cancer is the sixth most common cancer in the United States, and 70% of cases are non–muscle invasive. Intravesical bacillus Calmette-Guérin (BCG) immunotherapy, administered after transurethral tumor resection, is the most effective adjuvant treatment for intermediate-and high-grade non–muscle-invasive bladder cancer. Despite its weakened state, BCG has the potential to cause multisystem disease in treated patients. Although minor side effects following BCG administration are common, complications are rare. The pathogenesis of BCG-related disease may be active infection or a hypersensitivity reaction, and complications can involve many organ systems. Local complications result from BCG-contaminated urine and affect the genitourinary system. Systemic complications are the result of BCG dissemination in the bloodstream, and they may be musculoskeletal, vascular, pulmonary, or hepatic or involve other organ systems. Because the imaging findings of BCG-related complications can mimic those of cancer or infection by another organism, knowledge of prior BCG therapy and awareness of the potential related complications are essential for making the correct diagnosis prospectively and guiding appropriate treatment without delay.

Original languageEnglish (US)
Pages (from-to)80-94
Number of pages15
JournalRadiographics
Volume39
Issue number1
DOIs
StatePublished - Jan 1 2019

Fingerprint

Urinary Bladder Neoplasms
Immunotherapy
Bacillus
Urogenital System
Neoplasms
Infection
Blood Vessels
Hypersensitivity
Therapeutics
Urine
Lung
Liver

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Complications of intravesical bcg immunotherapy for bladder cancer. / Green, Daniel B.; Kawashima, Akira; Menias, Christine O.; Tanaka, Takashi; Redelman-Sidi, Gil; Bhalla, Sanjeev; Shah, Rakesh; King, Bernard Francis.

In: Radiographics, Vol. 39, No. 1, 01.01.2019, p. 80-94.

Research output: Contribution to journalArticle

Green, DB, Kawashima, A, Menias, CO, Tanaka, T, Redelman-Sidi, G, Bhalla, S, Shah, R & King, BF 2019, 'Complications of intravesical bcg immunotherapy for bladder cancer', Radiographics, vol. 39, no. 1, pp. 80-94. https://doi.org/10.1148/rg.2019180014
Green DB, Kawashima A, Menias CO, Tanaka T, Redelman-Sidi G, Bhalla S et al. Complications of intravesical bcg immunotherapy for bladder cancer. Radiographics. 2019 Jan 1;39(1):80-94. https://doi.org/10.1148/rg.2019180014
Green, Daniel B. ; Kawashima, Akira ; Menias, Christine O. ; Tanaka, Takashi ; Redelman-Sidi, Gil ; Bhalla, Sanjeev ; Shah, Rakesh ; King, Bernard Francis. / Complications of intravesical bcg immunotherapy for bladder cancer. In: Radiographics. 2019 ; Vol. 39, No. 1. pp. 80-94.
@article{f6001b6be4204a2dba0ffde1908f974e,
title = "Complications of intravesical bcg immunotherapy for bladder cancer",
abstract = "Bladder cancer is the sixth most common cancer in the United States, and 70{\%} of cases are non–muscle invasive. Intravesical bacillus Calmette-Gu{\'e}rin (BCG) immunotherapy, administered after transurethral tumor resection, is the most effective adjuvant treatment for intermediate-and high-grade non–muscle-invasive bladder cancer. Despite its weakened state, BCG has the potential to cause multisystem disease in treated patients. Although minor side effects following BCG administration are common, complications are rare. The pathogenesis of BCG-related disease may be active infection or a hypersensitivity reaction, and complications can involve many organ systems. Local complications result from BCG-contaminated urine and affect the genitourinary system. Systemic complications are the result of BCG dissemination in the bloodstream, and they may be musculoskeletal, vascular, pulmonary, or hepatic or involve other organ systems. Because the imaging findings of BCG-related complications can mimic those of cancer or infection by another organism, knowledge of prior BCG therapy and awareness of the potential related complications are essential for making the correct diagnosis prospectively and guiding appropriate treatment without delay.",
author = "Green, {Daniel B.} and Akira Kawashima and Menias, {Christine O.} and Takashi Tanaka and Gil Redelman-Sidi and Sanjeev Bhalla and Rakesh Shah and King, {Bernard Francis}",
year = "2019",
month = "1",
day = "1",
doi = "10.1148/rg.2019180014",
language = "English (US)",
volume = "39",
pages = "80--94",
journal = "Radiographics",
issn = "0271-5333",
publisher = "Radiological Society of North America Inc.",
number = "1",

}

TY - JOUR

T1 - Complications of intravesical bcg immunotherapy for bladder cancer

AU - Green, Daniel B.

AU - Kawashima, Akira

AU - Menias, Christine O.

AU - Tanaka, Takashi

AU - Redelman-Sidi, Gil

AU - Bhalla, Sanjeev

AU - Shah, Rakesh

AU - King, Bernard Francis

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Bladder cancer is the sixth most common cancer in the United States, and 70% of cases are non–muscle invasive. Intravesical bacillus Calmette-Guérin (BCG) immunotherapy, administered after transurethral tumor resection, is the most effective adjuvant treatment for intermediate-and high-grade non–muscle-invasive bladder cancer. Despite its weakened state, BCG has the potential to cause multisystem disease in treated patients. Although minor side effects following BCG administration are common, complications are rare. The pathogenesis of BCG-related disease may be active infection or a hypersensitivity reaction, and complications can involve many organ systems. Local complications result from BCG-contaminated urine and affect the genitourinary system. Systemic complications are the result of BCG dissemination in the bloodstream, and they may be musculoskeletal, vascular, pulmonary, or hepatic or involve other organ systems. Because the imaging findings of BCG-related complications can mimic those of cancer or infection by another organism, knowledge of prior BCG therapy and awareness of the potential related complications are essential for making the correct diagnosis prospectively and guiding appropriate treatment without delay.

AB - Bladder cancer is the sixth most common cancer in the United States, and 70% of cases are non–muscle invasive. Intravesical bacillus Calmette-Guérin (BCG) immunotherapy, administered after transurethral tumor resection, is the most effective adjuvant treatment for intermediate-and high-grade non–muscle-invasive bladder cancer. Despite its weakened state, BCG has the potential to cause multisystem disease in treated patients. Although minor side effects following BCG administration are common, complications are rare. The pathogenesis of BCG-related disease may be active infection or a hypersensitivity reaction, and complications can involve many organ systems. Local complications result from BCG-contaminated urine and affect the genitourinary system. Systemic complications are the result of BCG dissemination in the bloodstream, and they may be musculoskeletal, vascular, pulmonary, or hepatic or involve other organ systems. Because the imaging findings of BCG-related complications can mimic those of cancer or infection by another organism, knowledge of prior BCG therapy and awareness of the potential related complications are essential for making the correct diagnosis prospectively and guiding appropriate treatment without delay.

UR - http://www.scopus.com/inward/record.url?scp=85059795579&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85059795579&partnerID=8YFLogxK

U2 - 10.1148/rg.2019180014

DO - 10.1148/rg.2019180014

M3 - Article

VL - 39

SP - 80

EP - 94

JO - Radiographics

JF - Radiographics

SN - 0271-5333

IS - 1

ER -